文献速递脊柱关节炎

ASAS 健康指数在接受依奇珠单抗治疗的轴性脊柱关节炎患者中的区分能力

Discriminating capacity of the ASAS health index in patients with axial spondyloarthritis treated with ixekizumab.
PubMed 文献 · Semin Arthritis Rheum · 2025-06-27

在 COAST-V、COAST-W 和 COAST-X 三项安慰剂对照试验中,评估 ASAS 健康指数(ASAS HI)绝对与相对改善阈值对轴性脊柱关节炎(axSpA)患者治疗组与安慰剂组的区分能力。第 16 周时 ASAS HI ≥30% 改善阈值在全部三项试验中均能有效区分治疗分配;较低阈值在 COAST-W 有效,较高阈值在 COAST-V 有效,COAST-X 中 ≥30%、≥40%、≥50% 阈值有效。

要点

  • ASAS HI ≥30% 改善阈值在第 16 周可区分全部三项 COAST 试验的治疗组与安慰剂组。
  • COAST-W 中较低绝对(≥2.0-≥3.0 分)和相对(≥20%-≥30%)阈值区分有效。
  • COAST-V 中较高绝对(≥3.5-≥4.0 分)和相对(≥30%-≥50%)阈值区分有效。

核心结论

  • 多种 ASAS HI 改善阈值在第 16 周可区分 axSpA 患者治疗组与安慰剂组。
  • ASAS HI ≥30% 改善阈值在三项 COAST 试验中均具有区分能力。

研究设计与样本

  • 基于三项安慰剂对照试验(COAST-V、COAST-W、COAST-X)的分析,比较依奇珠单抗每 4 周一次(IXE Q4W)与安慰剂。
  • 基线及第 16 周有 ASAS HI 数据的 IXE Q4W 组和安慰剂组患者共 587 例。
  • 采用 Fisher 精确检验比较各阈值应答率,用比值比和 phi 系数评估阈值与治疗分配的关联,缺失数据采用无应答者填补。

主要发现

  • ASAS HI ≥30% 改善阈值在 r-axSpA(COAST-V:p = 0.026;COAST-W:p = 0.023)和 nr-axSpA(COAST-X:p = 0.040)中均显示 IXE Q4W 与安慰剂组间有显著差异。
  • COAST-W 中较低绝对(≥2.0-≥3.0 分)和相对(≥20%-≥30%)阈值区分有效。
  • COAST-V 中较高绝对(≥3.5-≥4.0 分)和相对(≥30%-≥50%)阈值区分有效。
  • COAST-X 中 ≥30%、≥40% 和 ≥50% 阈值区分有效。
  • 所有试验和阈值下 phi 系数均较小(<0.3)。

关键数值与推荐

  • ASAS HI 绝对改善阈值范围 ≥2.0 至 ≥4.0 分,相对改善阈值范围 ≥20% 至 ≥50%。
  • 第 16 周 ASAS HI ≥30% 改善阈值在 COAST-V(p = 0.026)、COAST-W(p = 0.023)和 COAST-X(p = 0.040)中区分治疗分配。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 所有试验和阈值下 phi 系数均较小(<0.3)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To test the discriminating capacity of different thresholds of the Assessment of SpondyloArthritis international Society Health Index (ASAS HI) in placebo-controlled trials of patients with axial spondyloarthritis (axSpA), including radiographic (r-axSpA) and non-radiographic (nr-axSpA) subtypes. METHODS: The discriminating capacities of absolute (≥2.0-≥4.0 points) and relative (≥20%-≥50%) ASAS HI improvement thresholds were evaluated in patients with axSpA from three COAST trials (COAST-V, COAST-W, and COAST-X) of ixekizumab every 4 weeks (IXE Q4W) vs. placebo. Threshold-based response rates at Week 16 were compared between trial arms using Fisher's exact test. Odds ratios and phi coefficients were used to evaluate how strongly each improvement threshold was associated with treatment allocation in a given trial. Missing data were handled using non-responder imputation. RESULTS: ASAS HI data were available at baseline and Week 16 for 587 patients in IXE Q4W and placebo arms. The ASAS HI ≥30% improvement threshold effectively discriminated treatment allocation in all trials; significant differences were observed between IXE Q4W and placebo in r-axSpA (COAST-V: p = 0.026; COAST-W: p = 0.023) and nr-axSpA (COAST-X: p = 0.040). Lower absolute (≥2.0-≥3.0 points) and relative (≥20%-≥30%) thresholds discriminated effectively in COAST-W, whereas higher absolute (≥3.5-≥4.0 points) and relative (≥30%-≥50%) thresholds discriminated effectively in COAST-V. In COAST-X, ≥30%, ≥40%, and ≥50% thresholds discriminated effectively. Phi coefficients were small (<0.3) across all trials and thresholds. CONCLUSIONS: Several ASAS HI improvement thresholds discriminated axSpA patients in treatment vs. placebo arms at Week 16. The ASAS HI ≥30% improvement threshold discriminated across all three COAST trials.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Kiltz U, Moltó A, van der Heijde D, et al. Discriminating capacity of the ASAS health index in patients with axial spondyloarthritis treated with ixekizumab. Semin Arthritis Rheum. 2025. PMID: 40644736. doi:10.1016/j.semarthrit.2025.152777

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。